Global procurement for COVID-19 vaccines
Available in English, French, Portuguese and Arabic
Successful immunization of a critical mass of the African population with one or several safe and efficacious COVID-19 vaccines.Key objectives1. Accelerate African involvement in the clinical development of a vaccine. 2. Ensur...e African countries can access a sufficient share of the global vaccine supply.3. Remove barriers to widespread delivery and uptake of effective vaccines across Africa.
more
تطوير لقاح مرض فيروس كورونا ] واستراتيجية المستجد [COVID-19
In this unit we will learn about vaccines and what is the progress made for developing a vaccine for COVID-19
Jesuit Worldwide Learning invites you to learn facts and test your knowledge on the ongoing pandemic caused by Coronavirus (COVID 19) through a fun-interactive crash course! Access is free!... You have only to sign up
more
WHO technical advisory group on behavioural insights and sciences for health, meeting report, 15 October 2020
Early data from US biotech Moderna has revealed that its Covid-19 vaccine candidate is 94.5 per cent effective, raising hopes that a range of immunisations will be available to help end the pandemic.
The interim analysis of the vaccine, currently known as mRNA-1273, comes after 95 trial particip...ants contracted Covid-19, including just five who were given the coronavirus jab.
more
Exciting news this week with @Pfizer reporting their mRNA vaccine is 90% effective, based on their Phase III clinical trial data. Dr. Tom looks inside the virus to break down how mRNA vaccines work, and whether news this promising means we can finally relax.
This document is part three in a series of explainers on vaccine development and distribution. Part one focused on how vaccines work to protect our bodies from disease-carrying germs. Part two focused on the ingredients in a vaccine and the three clinical trial phases.
This document outlines the... next part of the vaccine journey: the steps from completing the clinical trial phases through to distribution.
more
В настоящей Системе ценностей изложены рекомендации
глобального масштаба по распределению вакцин против
COVID-19 между странами, а также рекомендации
национальног...о уровня по определению приоритетности
групп для получения вакцинации внутри стран в условиях
ограниченных поставок. Система ценностей будет полезна
политикам и экспертам-консультантам на глобальном,
региональном и национальном уровнях при принятии
решений о распределении вакцин против COVID-19 и
определении приоритетности их получения.
more
PhD Martin Moder, österreichischer Molekularbiologe, Autor populärwissenschaftlicher Bücher und Teil der Wissenschaftskabarettgruppe Science Busters, erklärt die Wirkweise und potentiellen Risiken der mRNA-Impfstoffe gegen COVID19
The authors state that researchers, governments and global agencies should proceed with particular care in the evaluation of candidate SARS-CoV-2 vaccines in LMICs, with effective communication to build trust and avoid generation of vaccine hesitancy. Vaccine efficacy is often highly variable betwee...n high-resource and low-resource settings
Archives of Disease in Childhood, vol.106 Issue 2
more
13 July 2021
The module provides an overview of factors to consider when monitoring the safety of COVID-19 vaccines administered to pregnant and breastfeeding women. It describes how national routine AEFI surveillance should be adapted to cater for this specific group of population using both pass...ive and active surveillance methods. Specific considerations and limitations of each method are provided as well as tools for implementation.
more
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Cet article fait partie d’une série d’explications à propos de la mise au point et de la distribution des vaccins.
Available in English, French, Spanisch, Arabic, Chinese and Russian
As vaccines get approved by national authorities, learn about National and WHO approval processes for vaccines and how safety is ensured during emergency approval of vaccines. Dr Mariângela Simão explains in Science in 5.